Artivila Therapeutics
Artivila Therapeutics (Ke Hui Zhi Yao) develops innovative therapeutics using a dual AI+HI (Artificial Intelligence + Human Intelligence) engine-driven drug discovery platform, focusing on oncology, autoimmune diseases, and neurodegenerative diseases. The company integrates computational chemistry, artificial intelligence, synthetic chemistry, analytical chemistry, life sciences, and pharmacology across multiple…
Funding snapshot
About
Artivila Therapeutics (Ke Hui Zhi Yao) develops innovative therapeutics using a dual AI+HI (Artificial Intelligence + Human Intelligence) engine-driven drug discovery platform, focusing on oncology, autoimmune diseases, and neurodegenerative diseases. The company integrates computational chemistry, artificial intelligence, synthetic chemistry, analytical chemistry, life sciences, and pharmacology across multiple disciplines to significantly reduce R&D costs, shorten development cycles, improve success rates, and unlock challenging research areas. The platform leverages advanced AI technology combined with the successful drug development experience of top scientists from multinational pharmaceutical companies to design and develop first-in-class innovative drugs with broad commercial potential. Artivila aims to discover new drug targets and address unmet medical needs by designing therapeutics that can change patient outcomes. Founded in 2018 and headquartered in Shenzhen, China, the company has raised approximately $22.8 million at the seed stage.
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based,
Oncology > Drugs > Diversified,
Neurology > Drugs > Neurodegenerative > Diversified,
Immunology > Drugs > Autoimmune Diseases
Team background
College Wise > Columbia University
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.
Raising like Artivila Therapeutics?
Analyze your pitch deck before your next raise.
Analyze My Deck →